Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

New product relieves tooth pain resulting from dental sensitivity 



UNIONDALE, N.Y., July 5 /PRNewswire/ -- According to a recent survey* conducted by Harris Interactive for new Orajel(R) Advanced Tooth Desensitizer, nearly half of all American adults (46 percent) have experienced sensitive teeth in the past five years. Of these sufferers, almost half either did nothing about their sensitive teeth or were not satisfied with their treatment options.

Now sensitive teeth sufferers have a revolutionary new way to treat sensitive teeth with the introduction of new Orajel(R) Advanced Tooth Desensitizer. Utilizing a patented, FDA-cleared formula previously available only through a dentist, this product relieves pain resulting from dental sensitivity in just one day with one treatment that takes only minutes to apply and lasts up to one month.

"So many people live with tooth sensitivity," says Chris Kammer, D.D.S., dental expert in private practice in Madison, Wisconsin, and founding member of the American Academy of Cosmetic Dentistry (AACD). "I find that many people don't like using sensitive teeth toothpastes because of the bad taste and the length of time it takes to actually feel some results."

According to the survey, tooth sensitivity has changed the lives of 55 percent of people suffering from dental sensitivity, and in fact, 41 percent admitted to actually having changed the way they ate or drank (e.g., using a straw, eating only on one side of their mouth, etc.) in order to live pain- free.

"Teeth sensitivity is more than just an annoyance -- it can have life- disrupting consequences for many people," says Kammer. "The availability of this new at-home treatment, Orajel(R) Advanced Tooth Desensitizer, will bring relief to many. One treatment takes only minutes to relieve painful tooth sensitivity for up to a month."

Among the reasons for sensitive teeth, the Orajel survey found the most common were teeth clenching or grinding (21 percent), receding gums (21 percent), and cracked or chipped teeth (18 percent). Of those living with the pain, only 40 percent talked to their dentist about the problem.

Forty-two percent of people who have experienced sensitive teeth in the past five years felt that sensitive teeth are more uncomfortable than canker sores, ingrown toenails, or constipation, and, when asked what food would be the hardest to give up if they had to due to sensitive teeth, 23 percent of American adults indicated it would be ice cream.

Pharma News Headlines

Cancer News

Cardiac News


Pharma industry news


Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

Viruses may help cure cancer by killing cancer cells

New product relieves tooth pain resulting from dental sensitivity 

Cervical Cancer detector may improve on Pap Smears

Dietary supplement capsule by Liqing banned in US

Cold Stone Creamery cake batter ice-creams recalled

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA approval for PEPFAR

Gates Foundation donates for a good cause

Paxil CR resupply in US pharmacies announced by GlaxoSmithKline

Viagra users not at risk of blindness: Pfizer

Stem cell research gets boost from Li Ka-shing

BiDil heart failure drug for black patients approved

Restless leg syndrome could be messing up your sleep

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

German Remedies launches Fludara Oral

Ranbaxy acquires generic product portfolio from Efarmes

Sandoz files seven ANDAs of drugs going off-patent

Elder Pharma plans unit, brand acquisition

Novasite Pharma buys PsyCheNomicS

Chemokine gets US patent for novel cancer drug

Roche gets USFDA approval for oral Xeloda

Nectar Lifesciences plans Rs 90 crore IPO 

Glaxo inks co-promotion pact with Eisai for Paritec

Early Intervention required to Prevent Diabetes

AIDS drug ahoy!

Novartis launches AMD patient counselling programme

Nanobac Life Sciences, UCSF to study kidney stones 

Surface Logix commences phase I trial for PDE-5 inhibitor

Temasek sets up $112 million pharma JV

Contraceptive from Neem, courtesy DRDO  

US FDA to source anti-HIV drugs from Indian firms  

Chemists boycott Glaxo, Novartis products  

Maharashtra phases out nerve tissue-based rabies vaccine  

Last long, really long - new sex drug soon  

Johnson and Johnson demonstrates coronary stent safety

Novartis has better breast cancer treatment

Pfizer's investigational drug reduces tumor growth

New labeling for beta-blocker Coreg 

Glaxo applies for FDA approval for Flaurix

Investigational drug for Acute Bipolar Mania And Schizophrenia

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma



Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us